What is new in wound healing?

Turkish Journal of Medical Sciences

Volumn 34, Issue 3, 2004, Pages 147-160

  Kumar, Senthil ^a,b   Wong, Peng Foo ^a   Leaper, David John ^a  

^a UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Biological therapy; Growth factors; Physical therapy; Wound healing

Indexed keywords

ADHESION; DRUG THERAPY; GENES; GROWTH KINETICS; MOLECULAR DYNAMICS; SKIN; TISSUE;

GENE THERAPY; WOUND ASSESSMENT; WOUND HEALING;

BIOMEDICAL ENGINEERING;

ALGINIC ACID; CALCIUM ALGINATE; CELL ADHESION MOLECULE; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 10; GAMMA INTERFERON; GENE PRODUCT; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; IODINE; MONENSIN; OPSITE; PLATELET DERIVED GROWTH FACTOR; POLYURETHAN; PROTEINASE; SILICONE; SILVER; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VIRUS VECTOR; ZINC;

ANTIINFLAMMATORY ACTIVITY; BIOENGINEERING; CADAVER; DEBRIDEMENT; DERMIS; ELECTRIC CURRENT; ELECTROSTIMULATION; FIBROBLAST CULTURE; FLY; FOAM; GENE THERAPY; HUMAN; HYPERBARIC OXYGEN; KERATINOCYTE; LARVA; MAGGOT THERAPY; PRESSURE; REVIEW; SKIN CULTURE; STEM CELL; THERAPY; TISSUE ENGINEERING; WARMING; WOUND DRESSING; WOUND HEALING;

EID: 2942618537     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14: 2123-33, 2000.
2. Gomez DE, Alonso DF, Yoshiji H et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 74: 111-22, 1997.
3. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair. Int J Mol Med 6: 391-407, 2000.
4. Koch AE, Halloran MM, Haskell CJ et al. Angiogenesis mediated by soluble forms of E-selectin and Vascular cell adhesion molecule-1. Nature 376: 517-9, 1995.
5. Winter GD. Formation of the scab and the rate of epithelialisation of superficial wounds in the skin of the young domestic pig. Nature 193: 293-294, 1962.
6. Winter GD. Effect of air exposure and occlusion on experimental human skin wounds. Nature 200: 378-379, 1963.
7. Winter GD, Scales JT. Effect of air drying and dressings on the surface of a wound. Nature 197: 91-92, 1963.
8. Nemeth AJ, Eaglstein WH, Taylor JR, et al. Faster healing and less pain in skin biopsy sites treated with an occlusive dressing. Arch Dermatol 127: 1679-83, 1991.
9. Leipziger LS, Glushko V, DiBernardo B et al. Dermal wound repair: role of collagen matrix implants and synthetic polymer dressings. J Am Acad Dermatol 12: 409-19, 1985.
10. Pirone LA. Monte KA, Shannon R et al. Wound healing under occlusion and non-occlusion in partial-thickness and full-thickness wounds in swine. Wounds 2: 74-81, 1990.
11. Wilson APR, Sturridge MF, Treasure T et al. A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. Lancet 1(8476): 311-12, 1986.
12. Bailey SI, Karran SE, Toyn K et al. Community surveillance of complications after hernia surgery. Brit Med J. 304: 469-471, 1992.
13. Bruce J, Russell EM, Mollison J, et al. The quality of measurement of surgical wound infection as the basis for monitoring: a systematic review. Journal of Hospital Infection. 49: 99-108, 2001.
14. Cutting KF, Harding KGH. Criteria for identifying wound infection. J Wound Care 3: 198-201, 1994.
15. Gardner SE, Frantz RA, Doebbeling BN. The validity of the clinical signs and symptoms used to identify localized chronic wound infection. Wound Rep Reg 9: 178-86, 2001.
16. Grayson ML, Gibbons GW, Balogh K et al. Probing to bone in infected pedal ulcers: A clinical sign of underlying osteomyelitis in diabetic patients. JAMA 273: 721-3, 1995.
17. Thompson P, Taddonio T, Tait M. Correlation between swab and biopsy for the quantitation of burn wound microflora. Proct Int Cong Burn Inj 8: 381-3, 1990.
18. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Rep Reg 8: 13-25, 2000.
19. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Rep Reg 4: 321-5, 1996.
20. Ladwig GP, Robson MC, Liu R et al. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Rep Reg 10: 26-37, 2002
21. Tarlton JF, Vickery CJ, Leaper DJ et al. Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase-9. Br J Dermatol. 137: 506-16, 1997.
22. Fleischmann W, Becker U, Bischoff M et al. Vacuum sealing indication, technique and results. Eur J Orthop Surg & Trauma 5: 37-40, 1995.
23. Argenta LC, Morykwas MJ. Vacuum assisted closure: a new method for wound control and treatment: Clinical experience. Ann Plast Surg. 38: 563-576, 1997.
24. Rabkin JM, Hunt TK. Local heat increases blood flow and oxygen tension in wounds. Arch Surg 122: 221-25, 1987.
25. Ikeda T, Tayefeh F, Sessler DI et al. Local radiant heating increases subcutaneous oxygen tension. Am J Surg 175: 33-37, 1998.
26. Melling AC, Ali B, Scott EM et al. Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomised controlled trial. Lancet. 358: 876-80, 2001.
27. Scott EM, Leaper DJ, Clark M et al. Effects of warming therapy on pressure ulcers - a randomised trial. AORN Journal 73: 921-38, 2001.
28. Ellis SL, Finn P, Noone M et al. Eradication of methicillin-resistant staphylococcus aureus from pressure sores using warming therapy. Surgical infections. 4: 53-55, 2003.
29. Gardner SE, Frantz RA, Schmidt FK. Effect of electrical stimulation on chronic wound healing: a meta-analysis. Wound Rep Reg 7: 495-503, 1997.
30. Sarma GR, Subrahmanyam S, Deenabandhu A et al. Exposure to pulsed magnetic fields in the treatment of plantar ulcers in leprosy patients - a pilot, randomised double blind controlled trial. Indian Journal of Leprosy 69: 241-50, 1997.
31. Man D, Man B, Plosker H. The influence of permanent magnetic field therapy on wound healing in suction lipectomy patients: a double blind study. Plastic and Reconstructive Surgery. 104: 2261-6, 1999.
32. Prete PE. Growth effects of Phaenicia sericata larval extracts on fibroblasts: mechanism for wound healing by maggot therapy. Life Sci 60: 505-10, 1997.
33. Chambers L, Woodrow S, Brown AP et al. Degradation of extracellular matrix components by defined proteases from the greenbottle fly larva Lucilia sericata used for chemical debridement of non-healing wounds. Br J Dermatol 148: 14-23, 2003.
34. Horobin, AJ, Shakesheff, KM, Woodrow S et al. Maggots and wound healing: an investigation of the effects of secretions from Lucilia sericata larvae upon interactions between human dermal fibroblasts and extracellular matrix components. Br J Dermatol 148: 923-933, 2003.
35. Phillips TJ. Keratinocyte grafts for wound healing. Clin Dermatol 12: 171-181, 1994.
36. Falanga V, Margolis D. Alvarez O et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogenic cultured skin equivalent. Arch Dermatol 134: 293-300, 1998.
37. Falanga V, Sabolinski M. A bilayered skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Rep Reg 7: 201-7, 1997.
38. Veves A, Falanga V, Armstrong DG et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomised multicentre clinical trial. Diabetes Care 24: 290-5, 2001.
39. Brem H, Balledux J, Bloom T et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent. Arch Surg 135: 627-634, 2000.
40. Noordenbos J, Dore C, Hansbrough JF. Safety and efficacy of TransCyte for the treatment of partial-thickness burns. J Burn Care Rehabil 20: 275-81, 1999.
41. Badavias EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol 139: 510-16, 2003.
42. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III, randomised, placebo-controlled, double-blind study. Diabetes care 21: 822-7, 1998.
43. d'Hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethyl cellulose aqueous based gel versus beclapermin in patients with nonhealing, lower extremity diabetic ulcers. Wounds 10: 69-73, 1998.
44. Smiell JM, Wieman TJ, Steed DL et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomised studies. Wound Rep Reg 7: 335-46, 1999.
45. Robson MC, Phillips LG, Thomason A et al. Platelet derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339: 23-5, 1992
46. Mustoe TA, Cutler NR, Allman RM et al. A phase II study to evaluate recombinant platelet-derived growth factor - BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 129: 213-9, 1994.
47. Robson MC, Phillips TJ, Falanga V et al. Randomised trial of topically applied Repifermin (rh-KGF-2) to accelerate wound healing in venous ulcers. Wound Rep Reg 9: 347-52, 2000.
48. Brown GL, Nanney LB, Griffin J et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 321: 76-9, 1989.
49. Cohen IK, Crossland MC, Garrett A et al. Topical application of epidermal growth factor onto partial-thickness wounds in human volunteers does not enhance reepithelialization. Plast Reconstr Surg 96: 251-4, 1995.
50. Greenhalgh DG, Rieman M. Effects of basic fibroblast growth factor on the healing of partial-thickness donor sites: A prospective, randomized, double-blinded trial. Wound Rep Reg 2: 113-6, 1994.
51. Brown GL, Curtsinger L, Jurkiewicz MJ et al. Stimulation of healing of chronic wounds by epidermal growth factor. Plast Reconstr Surg 88: 189-94, 1991.
52. Tsang MW, Wong WK, Hung CS et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 26: 1856-61, 2003.
53. Daniele S, Frati L, Fiore C et al. The effect of the epidermal growth factor (EGF) on the corneal epithelium in humans. Graefes Arch Clin Exp Ophthalmol 210: 159-65, 1979.
54. Falanga V, Eaglstein WH, Bucalo B et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 18: 604-606, 1992.
55. Robson MC, Phillips LG, Laurence WT et al. The safety and effects of topically applied recombinant basic fibroblast growth factor on healing of chronic pressure sores. Ann Surg 216; 401-8, 1992.
56. Chandler LA, Gu DL, Ma C et al. Matrix enabled gene transfer for cutaneous wound repair. Wound Rep Reg 8: 473, 2000.
57. Senet P, Bon FX, Benbunan M et al. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. Journal of Vascular Surgery. 38: 1342-8, 2003.
58. Wang C, Schwaitzberg S, Berliner E et al. Hyperbaric oxygen for treating wounds. Arch Surg 138: 272-9, 2003.
59. Edwards VJ, Yager DR, Cohen IK et al. Modified cotton gauze dressings that selectively absorb neutrophil elastase activity in solution. Wound Rep Reg 9: 50-58, 2001.
60. Rees RS, Adamson BF, Lindblad WJ. Use of a cell-based interactive wound dressing to enhance healing of excisional wounds in nude mice. Wound Rep Reg 9: 297-304, 2001.